Shingrix Vaccine Approved in China: Protecting High-Risk Groups from Shingles

The China National Medical Products Administration (NMPA) has approved Shingrix (GSK's Recombinant Zoster Vaccine) for adults aged 18 and over at increased risk of shingles due to immunodeficiency or immunosuppression. Shingles, caused by the reactivation of the varicella zoster virus, affects approximately six million people in China annually. This vaccine is a game-changer for those vulnerable to the disease, offering protection against the painful and debilitating symptoms of shingles, including post-herpetic neuralgia (PHN). Learn how this approval expands access to prevention for high-risk groups and supports China's adult immunization system. Keywords: Shingrix, Shingles Vaccine, Recombinant Zoster Vaccine, Immunodeficiency, Immunosuppression, NMPA Approval, GSK, Healthy China 2030, Adult Immunization, Disease Prevention.

Видео Shingrix Vaccine Approved in China: Protecting High-Risk Groups from Shingles канала The Creative Flow